Is a complete KLRS research report available?

No complete published report is available for Kalaris Therapeutics, Inc. (KLRS) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Kalaris Therapeutics, Inc. (KLRS)

NASDAQ: KLRS · USD

$3.73

-0.19 (-4.8%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-25 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first KLRS analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	88.7M
Net income (ttm)	-44.1M
EPS (ttm)	-$2.18
Shares out	23.8M
Volume	156,949
Price target	$18.7	+401.6%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -44.1M
EPS (ttm): -$2.18
Market cap: 88.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All KLRS indicators

Market & fundamental data

Available fields

167

Groups with data

Currency

USD

Showing 167 of 167 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001754068
Company name	Kalaris Therapeutics, Inc.
Country	United States
Country code	US
Cusip	482929106
Employees	20
Enterprise value	$-12M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US4829291065
Last refreshed	2026-07-25
Market cap	$88.7M
Market cap category	Micro-Cap
Price	$3.73
Price currency	USD
Sector	Healthcare
Sector PE	44.8
Sector PE Fwd	23.59
Sic	2836
Symbol	KLRS
Website	https://kalaristx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-48.2%
FCF yield	-46.69%
P/B ratio	1.31x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-44.1M
Net Income Growth Years	2%
Profit Per Employee	$-2.2M
ROA	-27.97
ROCE	-46.82
ROE	-66.6
ROIC	-44.48

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	34.68%
EPS Growth Quarters	5
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$109.8M
Cash	$97.2M
Current Assets	$98.5M
Current Liabilities	$8.1M
Debt	$1.4M
Debt Equity	$0.02
Equity	$68.6M
Liabilities	$41.2M
Long Term Assets	$11.3M
Long Term Liabilities	$33.2M
Net Cash	$103.5M
Net Cash By Market Cap	$113
Net Cash Growth	2.47%
Net Debt Equity	$-1.51
Tangible Book Value	$68.6M
Tangible Book Value Per Share	$2.98

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	12.19
Net Working Capital	$-6.5M
Quick ratio	12.03
Working Capital	$90.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-898.75%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	34.66%
200-day SMA	6.6
50-day SMA	4.55
50-day SMA vs 200-day SMA	50under200
All Time High	12.9
All Time High Change	-71.09%
All Time High Date	2025-03-20
All Time Low	2.14
All Time Low Change	74.3%
All Time Low Date	2025-08-14
ATR	0.45
Beta1y	1.67
Beta2y	1.66
Ch YTD	-55.81
High	3.97
High52	11.88
High52 Date	2025-12-18
High52ch	-68.6%
Low	3.52
Low52	2.14
Low52 Date	2025-08-14
Low52ch	74.3%
Ma50ch	-18.08%
Price vs 200-day SMA	-43.47%
RSI	34.31
RSI Monthly	38.95
RSI Weekly	33.6
Sharpe ratio	0.77x
Sortino ratio	1.36
Total Return	-898.75%
Tr YTD	-55.81
Tr1m	-16.55%
Tr1w	-14.84%
Tr3m	-38.85%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	4
Analyst Price Target Top	$15.33
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.5
Operating Income	$-47.6M
Price target	$18.71
Price Target Change	$402
Price Target Change Top	$311

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	7,219,041%
Float Percent	30.34%
Shares Insiders	6.02%
Shares Institutions	17.55%
Shares Out	23,792,278
Shares Qo Q	21.95%
Shares Yo Y	898.75%
Short Float	6.96%
Short Ratio	6.12
Short Shares	2.11

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-44.9M
Average Volume	656,672.65x
Bv Per Share	2.98
CAPEX	$-200,000
Ch1m	-16.55
Ch1w	-14.84
Ch1y	34.66
Ch3m	-38.85
Ch6m	-61.94
Change	-4.85%
Change From Open	-3.62
Close	3.92
Days Gap	-1.28
Depreciation Amortization	23,000
Dollar Volume	585,419.8
Earnings Date	2026-08-12
Earnings Time	bmo
EBIT	$-47.6M
EBITDA	$-47.6M
EPS	$-2.18
F Score	1
FCF	$-42.7M
FCF EV Yield	356.58x
FCF Per Share	$-1.8
Financing CF	46,045,000
Fiscal Year End	December
Founded	2,019
Investing CF	-70,073,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-12
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-17
Ma150	6.89
Ma150ch	-45.82%
Ma20	4.38
Ma20ch	-14.78%
Net CF	-66,538,000
Next Earnings Date	2026-08-12
Open	3.87
Optionable	No
Position In Range	47.19
Post Close	3.73
Postmarket Change Percent	12.6
Postmarket Price	$4.2
Ppne	1,433,000
Price Date	2026-07-24
Ptbv Ratio	1.33
Relative Volume	0.24x
Share Based Comp	2,142,000
Tr6m	-61.94%
Us State	New Jersey
Volume	156,949

Kalaris Therapeutics, Inc. (KLRS)

Coverage state: Market snapshot only — no published research

Generate the first KLRS analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · KLRS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All KLRS indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on KLRS

Frequently asked questions